A randomised controlled trial of intramuscular syntometrine and intravenous oxytocin in the management of the third stage of labour.
OBJECTIVE
To compare the efficacy and safety of intravenous oxytocin with intramuscular syntometrine in the management of the third stage of labour.


METHODS
A prospective randomised trial.


METHODS
A university teaching hospital.


METHODS
A total of 991 women having a singleton pregnancy and vaginal delivery were randomised by a computer-generated number to receive either 1 ml syntometrine intramuscularly or 10 units of intravenous Syntocinon after delivery of the anterior shoulder of the fetus.


METHODS
Blood loss during delivery, rate of postpartum haemorrhage, need for repeated oxytocics, haemoglobin level before and 24 hours after delivery, duration of third stage, need for manual removal of placenta and sides effects including hypertension, nausea, vomiting, headache and chest pain.


RESULTS
The use of intravenous oxytocin was associated with a reduction in postpartum blood loss (P < 0.001) but there was no difference in the risk of postpartum haemorrhage in the need for repeated oxytocic injections and the drop in peripartum haemoglobin level between the two groups. There was also no difference in the risk of prolonged third stage, or in the need for manual removal of placenta. The use of syntometrine was associated with a higher risk of hypertension (RR 2.39, 95% CI 1.00-5.70). Other side effects were mild in nature with no differences between the two groups.


CONCLUSIONS
There are no important clinical differences in the effectiveness of intramuscular syntometrine and intravenous oxytocin for the prevention of postpartum blood loss. Intravenous oxytocin is less likely to cause hypertension.
Choy
C M Y
CM
Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong.
Lau
W C
WC
Tam
W H
WH
Yuen
P M
PM
D000328:Adult; D004874:Ergonovine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007273:Injections, Intramuscular; D007749:Labor Stage, Third / Q000187:drug effects*; D010120:Oxytocics / Q000008:administration & dosage* / Q000009:adverse effects; D010121:Oxytocin / Q000008:administration & dosage* / Q000009:adverse effects; D006473:Postpartum Hemorrhage / Q000517:prevention & control; D011247:Pregnancy; D011446:Prospective Studies; D011644:Puerperal Disorders / Q000139:chemically induced; D012307:Risk Factors; D014839:Vomiting / Q000139:chemically induced
D006454:Hemoglobins; D010120:Oxytocics; C038346:syntometrine; D010121:Oxytocin; D004874:Ergonovine